1-3 of 3
Tom Lillie, MD
Close
Sort by
Journal Articles

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Lee Schwartzberg, MD, Timothy Rearden, MD, Lorrin Yee, MD, Barry Mirtsching, MD, Veena Charu, MD, Hung Lam, PhD, Tom Lillie, MD/PhD, Ronald Burkes, MD, Peter Silberstein, MD
Journal: Blood
Blood (2006) 108 (11): 1306.
https://doi.org/10.1182/blood.V108.11.1306.1306
Published: 2006
Journal Articles

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

David H. Gordon, MD, Gwen Nichols, MD, Ali Ben-Jacob, MD, Hung Lam, PhD, Tom Lillie, MD, PhD, Carole Miller, MD
Journal: Blood
Blood (2006) 108 (11): 1304.
https://doi.org/10.1182/blood.V108.11.1304.1304
Published: 2006
Journal Articles

Effect of Dose Reductions on Response to 500-μg Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.

Jean-Luc Canon, MD, Johan Vansteenkiste, MD, Gyorgy Bodoky, MD, Ma Victoria Mateos, MD, Laurent Bastit, MD, Irene Ferreira, PhD, Tom Lillie, MD
Journal: Blood
Blood (2005) 106 (11): 3558.
https://doi.org/10.1182/blood.V106.11.3558.3558
Published: 2005